InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th
InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System for carotid artery disease and stroke prevention, has announced it will report second quarter 2024 financial results on Tuesday, August 6th, before market open. The company will host a conference call and webcast at 8:30 am EDT to discuss financial results and provide a corporate update.
Investors can access the call via toll-free number 1-800-445-7795 or international number 1-785-424-1699, using Conference ID: IMD2Q24. A live webcast will be available on the company's website, with replay access after the call. This event offers an opportunity for stakeholders to gain insights into InspireMD's financial performance and business developments.
InspireMD (Nasdaq: NSPR), sviluppatore del sistema di stent per la prevenzione degli emboli CGuard™ per la malattia dell'arteria carotidea e la prevenzione dell'ictus, ha annunciato che riporterà i risultati finanziari del secondo trimestre 2024 martedì 6 agosto, prima dell'apertura del mercato. L'azienda ospiterà una conference call e webcast alle 8:30 EDT per discutere dei risultati finanziari e fornire aggiornamenti sull'azienda.
Gli investitori possono accedere alla chiamata tramite il numero verde 1-800-445-7795 o il numero internazionale 1-785-424-1699, utilizzando l'ID della conferenza: IMD2Q24. Un webcast in diretta sarà disponibile sul sito web dell'azienda, con accesso alla registrazione dopo la chiamata. Questo evento offre un'opportunità agli stakeholder di ottenere approfondimenti sulle performance finanziarie di InspireMD e sugli sviluppi aziendali.
InspireMD (Nasdaq: NSPR), desarrollador del sistema de stent para prevención de embolias CGuard™ para la enfermedad de la arteria carótida y la prevención de accidentes cerebrovasculares, ha anunciado que reportará sus resultados financieros del segundo trimestre de 2024 el martes 6 de agosto, antes de la apertura del mercado. La compañía llevará a cabo una conferencia telefónica y webcast a las 8:30 am EDT para discutir los resultados financieros y proporcionar una actualización corporativa.
Los inversores pueden acceder a la llamada a través del número gratuito 1-800-445-7795 o del número internacional 1-785-424-1699, utilizando el ID de la conferencia: IMD2Q24. Habrá un webcast en vivo disponible en el sitio web de la empresa, con acceso a la repetición después de la llamada. Este evento ofrece una oportunidad para que las partes interesadas obtengan información sobre el rendimiento financiero de InspireMD y los desarrollos comerciales.
InspireMD (Nasdaq: NSPR)는 경동맥 질환과 뇌졸중 예방을 위한 CGuard™ 색전 예방 스탠트 시스템의 개발업체로서, 2024년 2분기 재무 결과를 8월 6일 화요일에 시장 개장 전에 발표할 것이라고 발표했습니다. 회사는 8:30 AM EDT에 재무 결과에 대해 논의하고 기업 업데이트를 제공하기 위해 컨퍼런스 콜 및 웹캐스트를 개최합니다.
투자자는 무료전화 1-800-445-7795 또는 국제전화 1-785-424-1699를 통해 전화를 접속할 수 있으며, 회의 ID: IMD2Q24를 사용해야 합니다. 회사 웹사이트에서 실시간 웹캐스트가 제공되며, 콜 이후에도 재생 가능한 접근이 가능합니다. 이 이벤트는 이해관계자가 InspireMD의 재무 성과와 비즈니스 개발에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
InspireMD (Nasdaq: NSPR), développeur du système de stent de prévention des embolies CGuard™ pour les maladies de l'artère carotide et la prévention des AVC, a annoncé qu'il publiera ses résultats financiers du deuxième trimestre 2024 le mardi 6 août, avant l'ouverture des marchés. L'entreprise organisera une conférence téléphonique et un webcast à 8h30 EDT pour discuter des résultats financiers et fournir une mise à jour de l'entreprise.
Les investisseurs peuvent accéder à l'appel via le numéro sans frais 1-800-445-7795 ou le numéro international 1-785-424-1699, en utilisant l'ID de la conférence : IMD2Q24. Un webcast en direct sera disponible sur le site web de l'entreprise, avec accès à un replay après l'appel. Cet événement offre aux parties prenantes l'opportunité de mieux comprendre la performance financière d'InspireMD et l'évolution de son activité.
InspireMD (Nasdaq: NSPR), Entwickler des CGuard™ Embolic Prevention Stent Systems zur Behandlung von Karotiserkrankungen und zur Schlaganfallprävention, hat bekannt gegeben, dass es am Dienstag, den 6. August, vor Markteröffnung die Finanzergebnisse für das zweite Quartal 2024 veröffentlichen wird. Das Unternehmen wird um 8:30 Uhr EDT eine Konferenzschaltung und einen Webcast abhalten, um die Finanzergebnisse zu erörtern und ein Unternehmensupdate zu geben.
Investoren können an der Konferenz über die gebührenfreie Nummer 1-800-445-7795 oder die internationale Nummer 1-785-424-1699 teilnehmen, wobei die Konferenz-ID IMD2Q24 verwendet werden muss. Ein Live-Webcast wird auf der Unternehmenswebsite verfügbar sein, mit Zugriff auf die Wiederholung nach dem Anruf. Diese Veranstaltung bietet den Interessengruppen die Möglichkeit, Einblicke in die finanzielle Leistung und die Unternehmensentwicklung von InspireMD zu gewinnen.
- None.
- None.
-Conference call and webcast to be held at 8:30 a.m. EDT-
TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2024 financial results on Tuesday, August 6th, before the financial markets open.
Management will host a conference call and webcast with the investment community at 8:30 am (EDT) that same day to review financial results and provide an update on corporate developments.
| Title: | InspireMD Second Quarter 2024 Financial Results and Corporate Update Conference Call and Webcast |
| Date: | Tuesday, August 6th, 2024 |
| Time: | 8:30 a.m. ET |
| Conference Call Details: | Toll-Free: 1-800-445-7795 International: 1-785-424-1699 Conference ID: IMD2Q24 |
| The conference call will be webcast live from the Company’s website and will be available via the following links: | |
| Webcast: | Webcast link – click here https://www.inspiremd.com/en/investors/investor-relations/ |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. For example, the company is using forward looking statements when it discusses the expansion of its portfolio and potential indications and that the CGuard Carotid stent provides a foundational advantage for improved patient outcomes and prevention of stroke. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
investor-relations@inspiremd.com
FAQ
When will InspireMD (NSPR) report its Q2 2024 financial results?
What time is InspireMD's (NSPR) Q2 2024 earnings call scheduled for?
How can investors access InspireMD's (NSPR) Q2 2024 earnings call?
What product does InspireMD (NSPR) develop?
